Pulmagen develops novel and proprietary therapies that aim to provide improved relief for bronchodilator symptoms and treat the underlying inflammatory disease process. They plan to advance their programs through Phase II proof-of-concept clinical trials and seek strategic partners for later stage clinical development. Their pipeline includes therapies for COPD, asthma, and cystic fibrosis, which offer both symptomatic relief and a disease modifying effect.